Navigation Links
WuXi PharmaTech Named in Deloitte Technology Fast 50 China 2009 List for the Fifth Consecutive Year
Date:11/30/2009

SHANGHAI, Nov. 30 /PRNewswire-Asia/ -- WuXi PharmaTech (NYSE: WX), a leading pharmaceutical, biotechnology, and medical-device research and development outsourcing company with operations in China and the United States, announced that it had been selected to the Deloitte Technology Fast 50 China 2009 list for the fifth consecutive year. The list recognizes the 50 fastest-growing companies in China's technology, media, and telecommunications industries based on revenue growth rates over the previous three years. WuXi PharmaTech is one of only two companies to have won this award for five consecutive years.

(Logo: http://www.newscom.com/cgi-bin/prnh/20040705/CNM002LOGO )

"This recognition is a credit to the dedication and hard work of our employees and the high quality of service they deliver," said Dr. Ge Li, Chairman and Chief Executive Officer of WuXi PharmaTech. "Through expansion of our capabilities and capacity, both in China and the United States, we are building a broad and fully integrated platform of pharmaceutical R&D services for our customers. We are confident that our continued investment in this platform will generate strong future revenue growth."

    For more information, please contact:

    WuXi PharmaTech (Cayman) Inc.

     Ronald Aldridge (for investors)
     Director of Investor Relations
     Tel:   +1-201-585-2048
     Email: ir@wuxiapptec.com

     Stephanie Liu (for the media)
     WuXi PharmaTech (Cayman) Inc.
     Tel:   +86-21-5046-4362
     Email: pr@wuxiapptec.com

SOURCE WuXi PharmaTech (Cayman) Inc.


'/>"/>
SOURCE WuXi PharmaTech (Cayman) Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Quest PharmaTech Acquires Late-Stage Immunotherapeutic Antibody Pipeline
2. WuXi PharmaTech Announces Second-Quarter 2009 Results
3. WuXi PharmaTech Announces Shareholder Resolutions Adopted at 2009 Annual General Meeting
4. WuXi PharmaTech Schedules Second-Quarter 2009 Earnings Release
5. WuXi PharmaTech Receives Award from BASF
6. WuXi PharmaTech Named a Top Ten Chinese Outsourcing Enterprise
7. WuXi PharmaTech Appoints Felix Hsu as Senior Vice President of U.S. Operations
8. WuXi PharmaTech Appoints Wei-Min Chang as Vice President of Operations and General Manager of SynTheAll Manufacturing Facility, Eric Gu as Vice President of Business Development for Manufacturing Services
9. WuXi PharmaTech to Present at Third Annual Jefferies Healthcare Conference
10. WuXi PharmaTech Schedules First-Quarter 2009 Earnings Release
11. Pharmatech Oncology Selected to Present at Company Showcase at BIOZONA
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/6/2016)... NH and Albany, NY (PRWEB) , ... December ... ... leading control system integrator of custom industrial automation and IT solutions, today announced ... decades, Superior Controls has reliably delivered professionally executed automation and control systems integration ...
(Date:12/6/2016)... According to a new market research report ... Silicon), Application (Genomics, Proteomics, Capillary Electrophoresis, POC, Clinical, Environmental, Drug Delivery) ... is projected to reach USD 8.78 Billion by 2021 from USD ... forecast period (2016 to 2021). Continue ... ...
(Date:12/6/2016)... Calif. , Dec. 6, 2016  SRI ... to $150 million from the National Institutes of ... and the Division of AIDS (NIAID-DAIDS) to support ... other non-vaccine pre-exposure (PreP) agents. Under the seven-year ... preclinical product development services for candidate HIV-prevention products ...
(Date:12/6/2016)... , ... December 06, 2016 , ... ... and building management solutions headquartered in Aurora, Ohio, announced the opening of their ... North Carolina, the newly constructed facility is home to 200 employees focused on ...
Breaking Biology Technology:
(Date:11/22/2016)...   MedNet Solutions , an innovative SaaS-based eClinical ... research, is pleased to announce that the company has ... Sciences Awards as "Most Outstanding in eClinical Solutions" ... of recognition and growth for MedNet, which has effectively ... iMedNet ™ , MedNet,s flagship eClinical ...
(Date:11/17/2016)... Global Market Watch: Primarily supported by ownership types; ... Academics) market is to witness a value of US$37.1 billion ... Compounded Annual Growth Rate (CAGR) of 10.75% is foreseen from ... 2014-2020. North America is not way ... Europe at 9.56% respectively. Report Focus: ...
(Date:11/15/2016)...  Synthetic Biologics, Inc. (NYSE MKT: SYN), a ... gut microbiome, today announced the pricing of an ... common stock and warrants to purchase 50,000,000 shares ... the public of $1.00 per share and accompanying ... offering, excluding the proceeds, if any from the ...
Breaking Biology News(10 mins):